• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

    6/13/24 7:10:25 AM ET
    $LXEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LXEO alert in real time by email
    Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00
    Get the next $LXEO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LXEO

    DatePrice TargetRatingAnalyst
    6/13/2024$28.00Outperform
    Robert W. Baird
    6/6/2024$22.00Buy
    H.C. Wainwright
    11/28/2023$20.00Overweight
    JP Morgan
    11/28/2023$20.00Buy
    Stifel
    11/28/2023$19.00Outperform
    Leerink Partners
    11/28/2023$22.00Outperform
    RBC Capital Mkts
    11/28/2023$23.00Buy
    Chardan Capital Markets
    More analyst ratings

    $LXEO
    SEC Filings

    See more
    • Amendment: SEC Form S-3/A filed by Lexeo Therapeutics Inc.

      S-3/A - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      6/26/25 4:56:22 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Lexeo Therapeutics Inc.

      S-3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      6/13/25 4:09:22 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Lexeo Therapeutics Inc.

      DEFA14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)

      6/5/25 4:52:05 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

      Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a strategic partnership to develop therapies for genetic cardiac d

      6/24/25 7:30:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

      Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a securities purchase agreement with a select group of institutional and healthcare accredited investors to issue and sell an aggregate of 20,790,120 shares ("Shares") of its common sto

      5/27/25 7:31:10 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

      Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; interim clinical data update on track for second half of 2025 Redeployed $20 million to focus on clinical-stage programs; cash, cash equivalents and investments of $106.9 million expected to prov

      5/12/25 7:00:00 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Lexeo Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00

      6/13/24 7:10:25 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Lexeo Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00

      6/6/24 7:17:54 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan initiated coverage on Lexeo Therapeutics with a new price target

      JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00

      11/28/23 7:29:52 AM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LXEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cholmondeley Paula H bought $104,852 worth of shares (15,000 units at $6.99), increasing direct ownership by 96% to 30,627 units (SEC Form 4)

      4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)

      11/26/24 5:00:06 PM ET
      $LXEO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care